There is barely any other disease as particular as cancer which is why it makes it so hard to treat. The biotech company BioNTech AG in Mainz, Germany, believes it is close to a solution – with an approach that considers the genetic profile of each and every patient as well as their condition. The vision of personalised tumor vaccines, however, is blurred by an extremely complex research and production process. Our software helps to bring this vision a little closer to reality.

Tumors are created by random gene mutations and not one patient has the same clinical picture. BioNTech's vision is to tailor tumor medicine specifically for these unique clinical pictures. In other words: to apply genetic analysis techniques to identify mutations and to produce a proprietary medication that ultimately mobilises the patient's immune system against the mutant cells. 
Our software SIMATIC IT eBR (Electronic Batch Record) speeds up considerably activities in the lab and guarantees compliance with the strictest statutory provisions.  In production, the intelligent planning tool SIMATIC IT Preactor coordinates all the steps and allows hundreds of different medicines to be produced in parallel in the shortest possible time. This effectively reaches several important milestones along the road to market approval for personalised medicine and realizes the fastest way from the lab to practical applications.